Transactions on Materials, Biotechnology and Life Sciences
ISSN: 2960-1932, eISSN: 2960-2319 | Volume 8
MMTCS 2025

Bridging Traditional Wisdom and Modern Diagnostics: Optimizing Chronic Kidney Disease Management through Technological Integration of Traditional Chinese Medicine and Western Medicine

Shiqi Lan*

College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China

* Corresponding Author email: 1922183691@qq.com

Abstract. Chronic kidney disease (CKD) is a major and increasing issue for public health around the world and places a heavy burden on healthcare systems globally. Current western medical (WM) treatments are relatively developed but still face difficulties in stopping the advancement of the disease and addressing the complete and complicated symptomatology of the disease at later stages. Meanwhile, the use of traditional Chinese medicine (TCM) that comes with a whole-istic philosophy and rich experience over many years in treating diseases of the kidneys can work hand-in-hand with the accurate diagnoses and application therapies of WM to improve the outcomes for patients and make their quality of life better. Some among them are the rapid development of modern technologies like Artificial Intelligence (AI), big data analytics, wearable devices, and multi-omics technologies that can bridge the gap between the experiential knowledge inherent in TCM's pattern differentiation and WM's diagnostic precision, offering possibilities for realizing TCM theory as well as paving ways for making individualized and integrative treatment plans. This paper will review the existing CKD management within both WM and TCM paradigms, elaborate on how different modern technologies can foster integration in CKD diagnosis and treatment then explore the potential future prospects of this integrative model for optimizing CKD care.

Keywords: Chronic Kidney Disease; Integrative Medicine; Traditional Chinese Medicine; Western Medicine; Modern Technology.

1. Introduction

Chronic kidney disease (CKD) is now a major global public health issue. It is characterized by progressive loss of kidney function and places a heavy burden on health care systems worldwide [1]. The disease is highly prevalent, with diabetes being one of the major risk factors associated with an even higher prevalence of CKD. Western medicine (WM) has evolved excellent diagnostic acumen and several treatments, including dialysis and transplantation, to advance the treatment of established renal disease and end-stage symptoms, but it has almost no global efficiency in stopping the disease for all patients, reversing established renal damage, and holistic management of diversified symptoms, particularly in advanced stages. A key challenge remains the lack of early symptoms in most patients with chronic kidney disease, leading to a significant 'diagnostic gap' that hinders timely intervention, and emphasizes the pressing need for improved diagnostics and broad management.

Traditional Chinese medicine (TCM) has a very good complementary history over the millennia in successful kidney management with a focus on the holistic individual. The vital function system of "Kidney" (Shèn) in TCM places great value in diagnostic principles regarding the treatment of “Pattern Differentiation and Treatment” (biànzhèng lùnzhì) [2]. The few available evidence support that this systemic precision between TCM and WM might be well enough to fill the gap that exists for CKD patients, not in the wish of having an additive mode of action but rather a synergistic one in which WM intervenes in stabilizing physiological markers and TCM acts on constitutional disharmony and general well-being [3]. Such an evolving concept is presently directed towards individualized and preventive medical care.

The convergence of ancient medical wisdom with contemporary scientific innovation is increasingly facilitated by modern technologies, including Artificial Intelligence (AI), big data analytics, wearable devices, and multi-omics. These technologies serve as critical enablers, offering unprecedented opportunities to objectify TCM's diagnostic methods, elucidate the complex mechanisms of its therapies, and develop sophisticated, individualized integrative treatment protocols [4]. By fostering a deeper understanding and more robust application of both medical systems, such technological integration can accelerate the shift towards a more predictive, preventive, personalized, and participatory (P4) model of CKD management. This paper, therefore, aims to comprehensively review how these modern technologies can bridge TCM wisdom and WM diagnostics to optimize CKD care, while also exploring the attendant challenges, opportunities, and future prospects of this evolving integrative paradigm.

2. Current Paradigms in CKD Management: Dual Perspectives

2.1. Western Medical Diagnosis and Staged Management of CKD

The WM approach to CKD is characterized by a standardized system for diagnosis, staging, and management, heavily reliant on objective physiological and pathological markers. The diagnosis of CKD in WM combines a series of biochemical markers, primarily the estimated Glomerular Filtration Rate (eGFR) calculated from serum creatinine levels along with some other factors such as age and sex [5]. Diagnosis is based on a value of eGFR persistently <60 mL/min/1.73m² for more than three months. The degree of albuminuria, measured by the urine albumin-to-creatinine ratio (ACR), reflects the magnitude of kidney damage; diagnostic ACR is ≥30 mg/g. Ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI) scan the size and morphology of the kidneys and detect structural abnormalities [6]. Where non-invasive tests are inconclusive, the patient may need a kidney biopsy to establish the diagnosis and assess the degree and nature of the renal condition. This diagnosis setup classically follows a hierarchy moving from function and damage markers to structural imaging and then, if necessary, histological validation.

Accurate staging is basic to the treatment plan and prognosis in a case of CKD. The definition of CKD according to the “Kidney Disease Improving Global Outcomes (KDIGO)” guidelines is the structural or functional abnormality of the kidneys and its duration is observed or considered for more than 3 months, with health implications [7]. The current staging system, that is, Cause, GFR category, and Albuminuria category (CGA) staging includes the Cause of CKD, GFR category (G1-G5), and Albuminuria category (A1-A3). The categories for GFR begin from G1 (eGFR ≥90 mL/min/1.73 m², that is normal or high with markers of kidney damage) and goes up to G5 (eGFR <15 mL/min/1.73 m², that is kidney failure/ESRD). Albuminuria categories are A1 (ACR <30 mg/g, norm to mild increase), A2 (ACR 30-300 mg/g, moderately increased), and A3 (ACR >300 mg/g, high increase). Table 1 shows how these categories, when combined, place patients appropriately into a risk group due to the risk of disease progression as well as related complications. Prognostic factors go beyond GFR and albuminuria to bring in aspects such as age, CKD etiology, comorbidities, and lifestyle factors. The guidelines of KDIGO 2024 recommend the use of validated equations for as long as there is enough evidence supporting their use in predicting the risk of kidney failure among the patients with CKD stages G3-5 [7].

Table 1. KDIGO CKD Staging System (CGA Staging - Risk Stratification) [7].

GFR Category	Albuminuria Category (ACR mg/g): <30 (A1) (Normal to Mildly Increased)	Albuminuria Category (ACR mg/g): 30-300 (A2) (Moderately Increased)	Albuminuria Category (ACR mg/g): >300 (A3) (Severely Increased)
G1 ≥90 mL/min/1.73 m² (Normal or high) *	Low Risk (Green)	Moderate Risk (Yellow)	High Risk (Orange)
G2 60-89 mL/min/1.73 m² (Mildly decreased) *	Low Risk (Green)	Moderate Risk (Yellow)	High Risk (Orange)
G3a 45-59 mL/min/1.73 m² (Mildly to moderately decreased)	Moderate Risk (Yellow)	High Risk (Orange)	Very High Risk (Red)
G3b 30-44 mL/min/1.73 m² (Moderately to severely decreased)	High Risk (Orange)	Very High Risk (Red)	Very High Risk (Red)
G4 15-29 mL/min/1.73 m² (Severely decreased)	Very High Risk (Red)	Very High Risk (Red)	Very High Risk (Red)
G5 <15 mL/min/1.73 m² (Kidney failure)	Very High Risk (Red)	Very High Risk (Red)	Very High Risk (Red)

**Note: In GFR categories G1 and G2, CKD is diagnosed only if other markers of kidney damage (e.g., albuminuria, hematuria, pathological abnormalities detected by histology or imaging, history of kidney transplantation) are present. Risk levels are illustrative and often color-coded in guidelines.*

The management of CKD involves the treatment of the disease that caused it, a reduction in the risk of further disease progression, the treatment of complications, and preparation for renal replacement therapy if necessary. General principles that apply to all patients include lifestyle modification, with dietary salt restriction, physical exercise, smoking cessation, and the normalization of body weight [8]. This is combined with an ever-growing pharmacological treatment that encompasses strict control of arterial hypertension, most commonly with Angiotensin-Converting Enzyme (ACE) inhibitors or Angiotensin II Receptor Blockers (ARBs), and of the glycemia with metformin, Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors, and Glucagon-Like Peptide-1 (GLP-1) analogs [9]; statins for the lipids; and individual treatment for the most common complications such as anemia, mineral, and bone disorders of the kidney, fluid retention, and hyperkalemia and metabolic acidosis. Renal replacement therapy is the treatment for end-stage renal disease when it is irreversible and when associated with complete renal failure according to all definitions of renal function tests. It is often hemodialysis or peritoneal dialysis but preferably kidney transplantation if the patient is a candidate for transplantation [10]. Holistic conservative management stands as a big choice for treating some patients who might not be right for, or want to have, dialysis or a transplant. WM care is mostly based on guidelines, which helps give standard care but does not cover the whole patient experience or the small differences in individuals.

2.2. TCM Understanding and Intervention in CKD

TCM provides unique theoretical frameworks and rich clinical experiences in the treatment of renal diseases. In TCM, the "Kidney" (Shèn) system covers more wide physiological functions than the anatomical kidneys in WM; it is considered the "root of" (xiāntiān, congenital constitution) storing "Essence" (jīng) and governing bones, marrow production related to hearing, and hair health as well as growth, development, reproduction, aging, and willpower. The classifications of CKD under WM are covered by several disease categories in TCM, provided the syndrome and stage, such as "Guān Gé," "Lóng Bì," "Shuǐ Zhǒng," "Nì Dú," and "Shèn Láo".

The diagnostic and therapeutic approach in TCM is guided by the principles of "same disease, different names" and "different diseases, same treatment." A single WM diagnosis of CKD may correspond to multiple TCM patterns based on individual presentation. In turn, different WM diseases that present with the same core TCM pattern will receive similar TCM treatment. TCM considers the pathogenesis of CKD mainly in the perspective of "Root Deficiency and Branch Excess." That is a deficiency of Spleen and Kidney function marks the basis or the root, and accumulation shows manifestations or branches of pathogenic factors like damp-heat, blood stasis, and toxins. Also, TCM's whole look sees inter-organ ties; CKD, while mostly hurting the Kidney system, a lot involves the Spleen, Liver, and Heart, and also sees how mind-feelings push disease to get worse [11].

Differentiation of the pattern is the first step of TCM diagnosis and treatment. The four diagnostic techniques are used for a full assessment—looking, listening and asking, and touching, mainly taking the pulse of imbalance felt in a patient [12]. Common imbalances observed among CKD patients are different types of Spleen-Kidney Deficiencies (Pí Shèn Kuī Xū), like the deficiency of Spleen-Kidney Qi and other common imbalances; Qi-Yin, Spleen-Kidney Yang, Liver-Kidney Yin, and more critical Yin-Yang dual imbalances seen in the later stages. Other common patterns diagnosed include Qi Deficiency and Blood Stasis (Qì Xū Xuè Yū), Dampness and Heat accumulating either Shī Rè Yùn Jié or Shī Rè leading to the Kidney condition (Shī Rè Shāng Shèn) with Kidney deficiency accompanied by Dampness and Stasis (Shèn Xū Shī Yū). It is to be understood here that these TCM patterns are dynamic and tend to evolve as the disease progresses, calling for flexible and adaptive treatment strategies. For a summary illustrative of common patterns, their key manifestations, and general treatment principles, refer to Table 2.

Table 2. Common TCM Patterns in CKD, Key Manifestations, and General Treatment Principles.

TCM Pattern	Key Manifestations (Symptoms, Tongue, Pulse)	General Treatment Principle (Pinyin and English)
Spleen-Kidney Qi Deficiency (*Pí Shèn Qì Xū*)	Fatigue, poor appetite, loose stools, lumbar soreness, edema, pale and swollen tongue with teeth marks, weak pulse	Strengthen Spleen, Boost Qi, Tonify Kidney, Consolidate Essence (*Jiàn Pí Yì Qì, Bǔ Shèn Gù Jīng*)
Qi-Yin Deficiency (*Qì Yīn Liǎng Xū*)	Fatigue, dry mouth, night sweats, lumbar soreness, foamy urine, red tongue with scanty coating, fine pulse	Boost Qi, Nourish Yin (*Yì Qì Yǎng Yīn*)
Spleen-Kidney Yang Deficiency (*Pí Shèn Yáng Xū*)	Aversion to cold, cold limbs, lumbar cold pain, significant edema, scanty urine or clear nocturnal polyuria, pale/swollen/tender tongue with white slippery coating, deep-slow-weak pulse	Warm & Tonify Spleen/Kidney, Assist Yang, Promote Water Circulation (*Wēn Bǔ Pí Shèn, Zhù Yáng Xíng Shuǐ*)
Qi Deficiency & Blood Stasis (*Qì Xū Xuè Yū*)	Fatigue, dull complexion, scaly skin, fixed pain, dark/purple tongue or with petechiae/ecchymoses, choppy or fine-choppy pulse	Boost Qi, Activate Blood, Resolve Stasis, Unblock Collaterals (*Yì Qì Huó Xuè, Huà Yū Tōng Luò*)
Damp-Heat Accumulation (*Shī Rè Yùn Jié*)	Scanty-dark urine with burning sensation/pain, bitter/sticky taste in mouth, red tongue with yellow greasy coating, slippery-rapid pulse	Clear Heat, Drain Dampness, Detoxify, Resolve Turbidity (*Qīng Rè Lì Shī, Jiě Dú Huà Zhuó*)

TCM incorporates many therapeutic modalities in the management of CKD. The main intervention is Chinese herbal treatment, prescribes compound formulas finely adjusted to the pattern of differentiation: correcting underlying imbalances and reducing proteinuria while protecting renal function and relieving accompanying symptoms [13]. Acupuncture and Moxibustion serve symptomatic management in fatigue and pain related to CKD and uremic pruritus. Currently, research is going on whether these may also assist renal function. Tui Na has applications in pain of musculoskeletal origin and may also improve local circulation in patients with CKD. Other external herbal treatments are an herbal acupoint application, herbal bath therapy, Chinese herbal enema therapy, and hot compress or iontophoresis at the region of the kidneys. An important benefit of many outside TCM treatments is their maybe lower overall side effect profiles compared to inside medicines, which is very good for CKD patients who often have bad excretion of drugs and get many different medicines.

3. Methodological Framework: Technological Empowerment of Integrative Diagnosis and Treatment

3.1. Big Data Analytics and Machine Learning in CKD Risk Stratification and TCM Pattern Objectification

Big data analytics and machine learning (ML) algorithms are helpful in the processing of enormous patient data sets, which are heterogeneous and could include clinical indicators, genomic information, lifestyle data, and TCM diagnostic input, all of which the model learns to put together as input to the engineered intelligent CKD risk prediction system and contribute to the objectification of TCM

pattern differentiation [14, 15]. For example, old written, ML approaches accurately model the progression of chronic kidney disease by making inroads into the many interdependencies that earlier delayed timely intervention. Within the TCM domain, ML may organize diagnostic data—symptoms, signs, and tongue and pulse descriptions—to objectify and standardized pattern differentiation further. A vital strength of AI is in the ability to incorporate information from multiple sources; then, structural and symptomatic data can be merged with the results from laboratory testing and take on a uniform analytical approach with the four diagnostic findings in TCM. This promotes a more whole idea concerning the patient and, therefore, increases the accuracy and individualizes the mixed approach between TCM and WM diagnostics.

3.2. AI in Medical Image Analysis and TCM Diagnostic Modernization

AI has been a real game-changer in the analysis of medical images in WM and parallel to this, it has paved ways to objectify the traditional diagnostic techniques of TCM, such as checking the pulse and tongue. In WM, it becomes feasible for AI algorithms to automatically extract features from ultrasound images of the kidney to predict renal function; sometimes, their accuracy is even higher than that of experienced nephrologists [16]. AI also helps in image segmentation differential diagnosis, grading of the disease, and prognosis of the kidney disease, among others. Some of the deep learning frameworks are also leveraged to automate the detection of kidney diseases from CT images, as well as the analysis of immunofluorescence images—an important aspect of chronic kidney disease etiology determination. Attempts are also being made simultaneously to develop software for the intelligent recognition of signs of TCM diagnosis. Automated tongue diagnosis systems (ATDS) utilize machine learning and image processing to objectively capture tongue features, including color, shape, coating, and stasis spots [17]. Electronic systems for TCM pulse diagnosis use sensors and algorithms for recording radial artery pressure waveforms as electronic TCM pulse data and for finding the relationship between the extracted physical parameters and TCM pulse characteristics. The innovation of AI-boosted WM imaging with objectified TCM diagnostic data might be expected to lead to novel integrative biomarkers—combinations of imaging features and TCM signs—that for the future may turn out to be of even more significant diagnostic or prognostic value for more individual CKD subtypes or for further risk stratification.

3.3. Wearable Devices and Remote Health Monitoring for Continuous CKD Management

The continuous data collected would be much richer than what can be collected in intermittent clinical visits. Such technologies would support home-based monitoring as well as the development of an early warning system. In addition to that, by analyzing wearable data, remote health monitoring systems can pick slight deviation measures from the group’s baseline or early signs prone to complications for CKD patients [18]. This capability aligns remarkably well with TCM's principle for "preventive treatment" (Zhi Wei Bing), which means intervention before a fully manifested disease, overt and manifested disease. Wearable technology continuously monitors the slight imbalances that may relate to early deviations in TCM patterns. Data in this regard serves as physiological input for AI algorithms to analyze the interpretation relating to patterns of TCM. This, in turn, would make it feasible for the system to generate early warnings, with personalized lifestyle recommendations based on TCM being a very proactive and individualized way of health management.

3.4. Multi-Omics Technologies in Elucidating Disease Mechanisms and Chinese Herbal Medicine Actions

The suite of "omics" technologies encompasses genomics, proteomics, and metabolomics and underpins powerful approaches to achieving molecular, systemic levels of insight into disease pathology and treatment mechanisms [19]. These techniques serve great purpose in unveiling complex Chinese herbal medicine (CHM). More importantly, such multi-omics, often with network pharmacology, can show key molecular targets and signaling pathways relevant to interventions of

CHM by comparing pre- and post-treatment omics profiles since treatment with CHM, particularly the classical formula, involves several components acting on several targets. Omics have been applied in chronic kidney disease to identify not only biomarkers related to the progression of the disease and the response to treatment but also to study how CHM works at the specific level of mechanisms of chronic kidney disease and its specific complications, such as chronic kidney disease-mineral and bone disorder [20]. In the end, by showing what CHM does at a tiny level, omics studies can prove if tradition works, spot active compounds, lead the way in formula change for better use and safety, and give a shared proof base that makes it easy for TCM and WM workers to talk and work together.

4. Optimizing Integrated CKD Management: Strategies and Systems

4.1. Precision Medicine and Individualized Integrative Therapy

The use of modern technology in integrative CKD care has its main rationale in the principle of precision medicine, which involves the customization of treatment to the patient based on genetic, environmental, and lifestyle factors. The data involved comprise multi-omics data, WM clinical metrics, AI-automated TCM pattern differentiation, and lifestyle data from wearables to support an individualized TCM-WM treatment regimen for CKD founded on such a broad and rich multilevel dataset [21]. This means that, in principle, TCM is an ancient form of personalized medicine because TCM principles "patterns" can be redefined and deepened through AI and omics technologies, for example, correlated with specific biomarker profiles or genetic polymorphisms. This would enable more precise pattern differentiation and, hence, more specific herbal prescriptions or other TCM interventions. Genomic information has long been used to guide pharmacogenomics in the selection and dosing of WM drugs. It will be used to guide whether the patient will respond to CHM formulas or individual herbs. In the more general context of TCM-WM co-administrations, AI models likely to play a key role are analyses of drug components, herb components, known targets, and individual patient metabolism. These will help in predicting herb-drug interaction and hence ensure safe and effective co-therapy.

4.2. Virtual Reality (VR) and Augmented Reality (AR) in Patient Education and Rehabilitation

Augmented reality (AR) and virtual reality (VR) are the new technologies that will provide an experience that goes well beyond playing games, something that will now enable patients themselves to participate in the management of CKD by being better informed and involved. These technologies will be applied in the education of CKD patients presenting a visualization of their own disease, anatomy, and renal physiology so that the patient can understand different treatment regimens and the need for lifestyle changes; better than was possible with traditional text-based methods [22]. For example, AR shows how non-steroidal anti-inflammatory drugs (NSAIDs) may acutely harm the kidneys; VR experiences can take patients into the complicated realities of diabetic kidney disease. It is high health literacy and self-management skills that leave these two technologies with their immense abilities in a missed potential. Patients undertaking dialysis who pass through the program exercise based on VR technology experienced substantial gains in physiological functioning, such as improved ability to walk, and better psychological condition by reducing depression and anxiety, as well as a better sense of self-efficacy in such safe and engaging virtual environments. These technologies also give new ways for TCM health teaching; VR/AR could, for example show meridian paths and acupoint spots or use AR to teach the TCM features (like nature, flavor, and meridian tropism) of different foods and their likely effects on individual body constitutions, making unclear TCM ideas clearer.

4.3. Clinical Decision Support Systems (CDSS) for Integrative Care

Clinical Decision Support Systems (CDSS) will be responsible for aggregating the enormous and diverse knowledge of TCM and WM to support clinical decisions in the complex environment of

CKD. For integrative care, the effective operation of a CDSS stipulates the need for strong knowledge bases on principles of TCM (such as rule-based pattern identification, composition logic of a formula, herbal properties, and acupoint prescriptions) and conventional medicine (including diagnostic criteria, methods of staging, treatment guidelines, and evidence-based medicine) [23]. Knowledge graph technology has been proved to show one such meaningful way for organizing this multi-origin knowledge in the medical domain. AI-driven CDSS would then evaluate holistic patient data, covering both WM laboratory findings and imaging results and the TCM four diagnostic findings and pattern characteristics to help the clinician attain more accurate pattern differentiation, propose appropriate mixed therapeutic approaches based on TCM and WM, highlight potential herb-drug interactions, and optimize the entire treatment pathway. Such systems are of great value to those clinicians who do not command much knowledge of the discipline of integrative medicine. While CDSS enforces evidence-based standardized care, its intelligent algorithms further check patient variability and propose personalized adjustments, thus balancing between guideline adherence and individual therapy. Effective integrative CDSS development is challenged by difficulties in formalizing and representing TCM knowledge, heterogeneous data source standardization, high-quality training dataset acquisition, and complex clinical validation. An outline of the contribution of the various modern technologies to integrated TCM-WM CKD Management can be found in Table 3.

Table 3. Overview of Modern Technologies in Integrated TCM-WM CKD Management.

Technology Category	Role in WM Diagnosis/Treatment	Role in TCM Diagnosis/Treatment	Bridging/Integration Role in TCM-WM
AI/Machine Learning (AI/ML)	Risk prediction, image analysis, drug discovery, personalized treatment recommendations	Assisted *biànzhèng* (tongue, pulse analysis), formula optimization, research on correlation between *zhènghòu* (patterns) and biomarkers	Integrate multi-source data, identify TCM-WM correlations, build combined diagnostic models, optimize integrated treatment plans
Big Data	Epidemiological research, real-world evidence generation, public health surveillance	Mining TCM clinical experience, preserving expert (*míng lǎo zhōngyī*) knowledge, studying *zhènghòu* distribution patterns	Build large-scale integrative cohorts, validate combined efficacy, discover new diagnostic and treatment paradigms
Wearable Devices	Remote physiological parameter monitoring, early warning systems, lifestyle adherence tracking	Assists in judging states of *qì xuè yīn yáng* (e.g., via sleep, activity), data source for individualized intervention in *zhì wèi bìng*	Dynamically monitor effects of integrated therapy, provide personalized TCM-WM lifestyle guidance
Multi-Omics Technologies	Disease molecular subtyping, drug target discovery, pharmacogenomics	Elucidate CHM formula mechanisms, identify active compounds, research molecular basis of *zhènghòu*	Provide mechanistic basis for herb-drug co-administration, discover biomarkers for integrated therapy effectiveness and safety
Virtual/Augmented Reality (VR/AR)	Surgical simulation training, anatomical teaching, patient disease education, rehabilitation	Visualized teaching of TCM theories (e.g., *jīngluò shùxué* - meridians/acupoints), assisted practice of health Qigong (e.g., *Tàijí*)	Improve patient understanding of and adherence to complex integrated treatment plans, enhance rehabilitation experience
Clinical Decision Support Systems (CDSS)	Guideline-based diagnostic/treatment recommendations, drug interaction alerts, workflow standardization	Assistance with TCM *biànzhèng* logic, classic formula recommendations, alerts for CHM compatibility/contraindications	Integrate TCM-WM knowledge bases, provide combined diagnostic/treatment advice, prevent potential conflicts, elevate integrative care quality

5. Discussion: Challenges, Opportunities, and Future Outlook

5.1. Prevailing Challenges

The use of integrative TCM/WM passageway technology to allow treatments regulating promising results but is up against a host of challenges. Primarily, these are issues related to the data such as information silos, lack of interoperability, and very tough standardization of the rather elaborate TCM terminology to make it meaningful in data processing and AI model training. Large ethical and privacy issues are also involved in the handling of multi-dimensional sensitive health data, risks of algorithmic biases in AI, and AI decision processes that are in some "black boxes" that can affect the channels of responsibility and trust [24]. Even more, access is also blocked by technological and implementation barriers, including no common technical standards and great difficulty in moving new technological applications into long-standing clinical work processes. Human aspects, including the shortage of cross-cutting experts and different levels of uptake among workers and patients, alongside barriers and enablers such as complex approval pathways and insufficient reimbursement mechanisms, also quite significantly slow things down. A detailed itemized breakdown of these challenges and their potential impact on integrated CKD care is provided in Table 4.

Table 4. Key Challenges in Applying Modern Technologies to Integrated TCM-WM CKD Management.

Challenge Category	Specific Challenge	Potential Impact on Integrated CKD Care
Data-related	Data silos, lack of interoperability; difficulties in standardizing TCM data; insufficient high-quality datasets	Limits AI model development/validation, undermines evidence-base and scalability of integrated care
Ethical/Privacy	Patient data privacy risks; potential for AI algorithm bias; "black-box" decisions leading to unclear accountability and low trust	Compromises patient rights, may worsen health inequities, hinders clinical adoption of technologies and integrative models
Technological/ Implementation	Lack of unified technical standards; difficulty integrating new technologies into existing clinical workflows; hardware/software compatibility issues	Affects technology dissemination and effectiveness, increases implementation costs and complexity
Human Factors	Shortage of interdisciplinary talent; suboptimal acceptance/trust in new technologies and integrative models by clinicians and patients	Constrains innovation pace, impacts clinical outcomes and patient adherence
Regulatory/Policy	Complex and lengthy regulatory approval processes; lack of supportive reimbursement and pricing policies	Delays clinical translation of new technologies/therapies, limits their accessibility and sustainability

5.2. Future Development Opportunities

The fertile landscape, however, offers opportunities for advancing technology-driven TCM-WM integration in CKD care. The main driver is the increasing interdisciplinary fusion and research innovation under deepening collaborations across TCM, WM, data science, and engineering

theoretical and technological breakthroughs. National policies in most regions support the initiative, based on the value of traditional and complementary medicine, and encourage healthcare technology innovation, thus creating a favorable environment for developing models of integrated care for CKD. The other is more holistic, personal, and offers less side-effect care to the patient, therefore raising interest toward integrative approaches. The other is continuous technological development in AI, wearables, multi-omics, and big data analytics that offers ever more powerful and increasingly accessible tools. The aggregation of robust evidence-based support from well-conducted clinical trials and will be for increasing the adoption and clinical implementation of these potentially establishing a virtuous cycle of innovation, validation, and broader application.

5.3. Outlook: The Future of Integrated CKD Care

The future of integrated CKD care, technically empowered, changes the paradigm of care to health management by shifting the focus from cure-oriented AI application to prevention-oriented, proactive use of genomics and AI in early risk identification and personalized preventive strategies that work in integrating WM risk control with TCM preventive treatment. The individualized therapy that is to be created will consist of combined therapies matching the individual multi-omics profiles and clinical data as well as the AI-objectified TCM patterns using, in most cases, sophisticated CDSS. Patient empowerment and participatory medicine will be at the center, with the use of wearables and mobile health applications making a new degree of active participation possible. Healthcare institutions will turn into intelligent integrative nephrology centers that implement seamless holistic care. In the end, global cooperation and standardization of the sharing of data, research methods, and guidelines are necessary to bring the standards of CKD care to the level that promotes "Integrative Nephrology Intelligence" and, through this, a different handling of this complex chronic disease.

6. Conclusion

In summary, the burden of global health due to CKD is large and requires new approaches to its management. This paper has brought to light the great prospect of merging holistic knowledge from TCM with the accuracy of diagnosis in WM, particularly when supported by contemporary tools like AI, big data analysis, wearable sensors, and multi-omics. These tools will provide means for objectifying TCM diagnostics, exploring CHM’s mechanisms, and customizing treatment while also improving patient care, moving the route toward a more effective, accurate, and patient-centered approach to CKD care. While there are some significant challenges in terms of the data, ethics, implementation, human factors, and regulation that need to be addressed proactively, there is an unprecedented confluence of interdisciplinary innovation, enabling policies, patient pull, and ever-emerging technology push that creates real opportunities. To achieve such a future, it is important to combine efforts in the strengthening of high-quality clinical research, steps to standardize data, deepening mechanistic studies, developing a strong clinical decision support system, setting up clear ethical and regulatory frameworks, developing interdisciplinary talent, and improving patient education. The investment should be realized to unleash the power of these two seemingly disparate worlds-ancient wisdom and modern technology, such that they bring about a fundamental transformation in the management of CKD, and excellent outcomes and high quality of life for patients throughout the world.

References

[1] P. Cockwell, L.A. Fisher, The global burden of chronic kidney disease, The Lancet 395 (2020) 662-664.

[2] A.S. Ferreira, A.J. Lopes, Chinese medicine pattern differentiation and its implications for clinical practice, Chinese journal of integrative medicine 17 (2011) 818-823.

[3] K.W. Chan, T.Y. Chow, K.Y. Yu, Y. Feng, L. Lao, Z. Bian, S.C.W. Tang, Effectiveness of integrative Chinese–Western medicine for chronic kidney disease and diabetes: a retrospective cohort study, The American Journal of Chinese Medicine 50 (2022) 371-388.

[4] J.Y. Ng, H. Cramer, M.S. Lee, D. Moher, Traditional, complementary, and integrative medicine and artificial intelligence: Novel opportunities in healthcare, Integrative Medicine Research 13 (2024) 101024.

[5] G.J. Schwartz, S.L. Furth, Glomerular filtration rate measurement and estimation in chronic kidney disease, Pediatric nephrology 22 (2007) 1839-1848.

[6] N. Grenier, E. Quaia, P.V. Prasad, L. Juillard, Radiology imaging of renal structure and function by computed tomography, magnetic resonance imaging, and ultrasound, Seminars in nuclear medicine 41 (2011) 45-60.

[7] A. Levin, P.E. Stevens, R.W. Bilous, J. Coresh, A.L. De Francisco, P.E. De Jong, C.G. Winearls, KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease, Kidney international supplements 3 (2013) 1-150.

[8] L. Alkhatib, L.A.V. Diaz, S. Varma, A. Chowdhary, P. Bapat, H. Pan, K. Kalra, Lifestyle modifications and nutritional and therapeutic interventions in delaying the progression of chronic kidney disease: a review, Cureus 15 (2023).

[9] S.I. Taylor, Z.S. Yazdi, A.L. Beitelshees, Pharmacological treatment of hyperglycemia in type 2 diabetes, J. Clin. Investig. 131 (2021).

[10] F. Locatelli, P. Pozzoni, L. Del Vecchio, Renal replacement therapy in patients with diabetes and end-stage renal disease, J. Am. Soc. Nephrol. 15 (2004) S25-S29.

[11] D. Keown, The spark in the machine: How the science of acupuncture explains the mysteries of western medicine, Singing Dragon, 2014.

[12] A. Lu, M. Jiang, C. Zhang, K. Chan, An integrative approach of linking traditional Chinese medicine pattern classification and biomedicine diagnosis, J. Ethnopharmacol. 141 (2012) 549-556.

[13] Y. Zhong, Y. Deng, Y. Chen, P.Y. Chuang, J.C. He, Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases, Kidney international 84 (2013) 1108-1118.

[14] W.T. Huang, H.H. Hung, Y.W. Kao, S.C. Ou, Y.C. Lin, W.Z. Cheng, S.T. Huang, Application of neural network and cluster analyses to differentiate TCM patterns in patients with breast cancer, Frontiers in Pharmacology 11 (2020) 670.

[15] C. Zhao, G.Z. Li, C. Wang, J. Niu, Advances in patient classification for traditional Chinese medicine: a machine learning perspective, Evidence-Based Complementary and Alternative Medicine 2015 (2015) 376716.

[16] C.C. Kuo, C.M. Chang, K.T. Liu, W.K. Lin, H.Y. Chiang, C.W. Chung, K.T. Chen, Automation of the kidney function prediction and classification through ultrasound-based kidney imaging using deep learning, NPJ digital medicine 2 (2019) 29.

[17] M.H. Tania, K. Lwin, M.A. Hossain, Advances in automated tongue diagnosis techniques, Integrative Medicine Research 8 (2019) 42-56.

[18] E. Itelman, G. Shlomai, A. Leibowitz, S. Weinstein, M. Yakir, I. Tamir, G. Segal, Assessing the usability of a novel wearable remote patient monitoring device for the early detection of in-hospital patient deterioration: observational study, JMIR Formative Research 6 (2022) e36066.

[19] K.J. Karczewski, M.P. Snyder, Integrative omics for health and disease, Nature Reviews Genetics 19 (2018) 299-310.

[20] W. Ziyi, Z. Tingyu, W. Boyang, L. Shao, TCM network pharmacology: New perspective integrating network target with artificial intelligence and multi-modal multi-omics technologies, Chinese Journal of Natural Medicines (2024).

[21] G. Gembillo, R. Siligato, D. Santoro, Personalized medicine in kidney disease, J. Pers. Med. 13 (2023) 1501.

[22] W.C. Tsai, C.H. Kuo, C.F. Lee, Research on Augmented Reality Design of Diet for Elderly Patients with Chronic Kidney Disease, in: International Conference on Human-Computer Interaction, Springer, Cham, 2025, pp. 273-289.

[23] X. Zhou, S. Chen, B. Liu, R. Zhang, Y. Wang, P. Li, X. Yan, Development of traditional Chinese medicine clinical data warehouse for medical knowledge discovery and decision support, Artificial Intelligence in medicine 48 (2010) 139-152.

[24] N. Ali, W. Shah, Integrative Systems and Holistic Health Records: A New Paradigm in Personalized Medicine, 2025.